Compare HZO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | ANAB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1998 | 2015 |
| Metric | HZO | ANAB |
|---|---|---|
| Price | $52.85 | $46.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $49.40 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 741.7K | 324.4K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.13 | ★ 91.02 |
| EPS | N/A | ★ 0.11 |
| Revenue | ★ $2,163,989,000.00 | $234,603,000.00 |
| Revenue This Year | $5.97 | $31.89 |
| Revenue Next Year | $5.80 | $65.73 |
| P/E Ratio | ★ N/A | $430.55 |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $22.49 | $39.02 |
| 52 Week High | $52.90 | $73.30 |
| Indicator | HZO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.34 | 46.22 |
| Support Level | $52.23 | $44.35 |
| Resistance Level | $52.89 | $49.16 |
| Average True Range (ATR) | 0.08 | 1.90 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 75.00 | 43.59 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).